Trusted by:

clients clients clients clients clients clients clients clients clients clients
Released: 18-Feb-2016 10:05 AM EST
Late-Breaking Abstracts From ACTRIMS 2016 Now Available
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Can the degree of meningeal inflammation and cortical pathology be used to stratify early progressive MS patients? Roberta Magliozzi, Ph.D., Imperial College, London, UK

Released: 18-Feb-2016 10:05 AM EST
Late-Breaking Abstracts Now Available From ACTRIMS 2016
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Jennifer S. Graves M.D., Ph.D., University of California at San Francisco will present one of three late-breaking abstracts at ACTRIMS 2016

Released: 23-Feb-2016 5:05 PM EST
ACTRIMS 2016 Concludes With Young Investigator Awards
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Opportunities for young investigators to present their findings and consult with established researchers and clinicians were among the primary goals of ACTRIMS Forum 2016. The event drew more than 600 participants to New Orleans.

Released: 26-Feb-2016 11:05 AM EST
Late-Breaking Research Shows Promise for Patients with Primary Progressive Multiple Sclerosis
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Abstract describes efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial.

Released: 26-Feb-2018 12:05 PM EST
ACTRIMS Recognizes Young Investigators at Forum 2018
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) recognized the research contributions of five young investigators during the recent ACTRIMS Forum 2018. Abstracts and posters can be found in the ACTRIMS Forum online program, and will be published in the MS Journal.

Released: 27-Nov-2018 4:55 PM EST
Tailored Disability-Specific Neuroprotective Treatment Development in MS Offers a Potential New Approach
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Dr. Rhonda Voskuhl professor at the University of California, Los Angeles, will present her hypothesis that molecular mechanisms underlying each disability may differ from each other based on regional differences in neurons, astrocytes and oligodendrocytes as the subject of the keynote Kenneth P. Johnson Memorial Lecture on the opening day of the ACTRIMS Forum 2019.

Released: 6-Dec-2019 4:50 PM EST
Networks in multiple sclerosis will be the focus at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2020 Forum
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Approximately 1,200 researchers and clinicians are expected to attend the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual Forum Feb. 27-29, 2020, in West Palm Beach, Florida.

Released: 18-Feb-2020 3:25 PM EST
New Research Links Genetics and MS Severity, Offers Innovative Treatment Ideas to Combat MS and Other Neurodegenerative Diseases
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Dr. Peter Calabresi, professor of Neurology and Neuroscience at the Johns Hopkins School of Medicine and Director of the Johns Hopkins Multiple Sclerosis (MS) Center, will present his team’s discovery of a possible link between severe damage and C3 and C1q gene variants, and how this information could lead to improvements in the ways MS and other neurodegenerative diseases are treated, during his keynote Kenneth P. Johnson Memorial Lecture on the opening day of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2020.


close
1.93797